Related Experiment Videos
Hemodynamic effects of edrophonium chloride (Tensilon) infusion
Insights
Edrophonium chloride, when administered to patients with myocardial disease, showed no significant impact on cardiac function. Minor side effects like dizziness were noted in a small subset of patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Edrophonium chloride is an acetylcholinesterase inhibitor.
- Its hemodynamic effects in patients with myocardial disease require thorough investigation.
- Understanding drug safety in cardiac patients is crucial for clinical practice.
Purpose of the Study:
- To evaluate the hemodynamic effects of edrophonium chloride in unanesthetized patients with significant myocardial disease.
- To assess the impact of a specific dosing regimen (10 mg bolus followed by infusion) on cardiac function.
Main Methods:
- Hemodynamic parameters were measured in unanesthetized patients with myocardial disease.
- A 10 mg bolus of edrophonium chloride was administered, followed by a continuous infusion (0.25-1.0 mg/min).
- Heart rate effects were controlled in patients with complete heart block and pacemakers.
Main Results:
- No significant changes were observed in cardiac index, mean blood pressure, or ventricular ejection times.
- Two patients experienced transient dizziness, nausea, and abdominal cramps with a mild decrease in peripheral vascular resistance.
- The drug infusion did not adversely affect myocardial function in the study population.
Conclusions:
- A 10 mg bolus followed by continuous infusion of edrophonium chloride (0.25-1.0 mg/min) is hemodynamically safe in patients with myocardial disease.
- The drug does not significantly alter key indicators of cardiac performance.
- Further research may explore its utility in specific cardiac conditions, considering the noted mild side effects.
Abstract:
The hemodynamic effects of a 10 mg bolus of edrophonium chloride followed by a continuous infusion of 0.25 to 1.0 mg per minute, were determined in unanesthetized patients with significant myocardial disease. The effect on heart rate of the drug was negated by studying a group of nine patients with complete heart block and permanently implanted ventricular pacemakers. After the 10 mg bolus, two of the nine patients experienced dizziness, nausea and abdominal cramps associated with a mild decrease in peripheral vascular resistance. There was no significant change in cardiac index, mean blood pressure, brachial artery upstroke time, corrected ejection time, or left ventricular systolic ejection time. This study demonstrated that the continuous infusion of 0.25 to 1.0 mg per minute of edrophonium chloride following a 10 mg loading dose, had no significant effect on myocardial function.